Subtype
Malignant Urinary Tract Neoplasm
CI-CAN-00003252Explore in graph →
507 active trials14 approved drugs29 evidence items
- NCIt
- C192668
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003252Explore in graph →
Clinical trials
1,955 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (246)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03421652 | Nivolumab and RT in Treating Patients With Localized/Locally Advanced Urothelial Bladder Cancer Ineligible for Chemo | completed | Phase 2 | 20 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Aug 4, 2023 | clinicaltrials |
| NCT03602079 | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | completed | Phase 1 / Phase 2 | 49 | Klus Pharma Inc.INDUSTRY | 1 | Aug 3, 2023 | clinicaltrials |
| NCT02449239 | Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG(VISTA) | completed | Phase 3 | 133 | Sesen Bio, Inc.INDUSTRY | 2 | Jul 24, 2023 | clinicaltrials |
| NCT05946369 | Neutrophils to Lymphocytes Ratio in Predicting the Response to BCG in Non-muscle Invasive Bladder Cancer | completed | — | 96 | Ain Shams UniversityOTHER | 1 | Jul 18, 2023 | clinicaltrials |
| NCT04452214 | A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors | completed | Phase 1 | 19 | Cantargia ABINDUSTRY | 1 | Jul 14, 2023 | clinicaltrials |
| NCT05937555 | Professional Bladder Cancers and the Profession of Painter(NEVPP) | completed | — | 150 | University Hospital, BrestOTHER | 1 | Jul 10, 2023 | clinicaltrials |
| NCT03735680 | A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer | completed | Phase 2 | 30 | OncoNano Medicine, Inc.INDUSTRY | 1 | Jul 7, 2023 | clinicaltrials |
| NCT03829436 | TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers | completed | Phase 1 | 38 | Tempest TherapeuticsINDUSTRY | 1 | Jul 3, 2023 | clinicaltrials |
| NCT03171493 | Trial of Intravesical Measles Virotherapy in Patients With Bladder Cancer Who Are Undergoing Radical Cystectomy | completed | Phase 1 | 8 | Vyriad, Inc.INDUSTRY | 1 | Jun 27, 2023 | clinicaltrials |
| NCT00002914 | Piritrexim in Treating Patients With Advanced Cancer of the Urinary Tract | completed | Phase 2 | 40 | Eastern Cooperative Oncology GroupNETWORK | 2 | Jun 22, 2023 | clinicaltrials |
| NCT00003129 | Chemotherapy in Treating Patients With Early-Stage Bladder Cancer | completed | Phase 2 | 75 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 22, 2023 | clinicaltrials |
| NCT00003376 | Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium | completed | Phase 3 | 330 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 22, 2023 | clinicaltrials |
| NCT00005644 | Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Function | completed | Phase 2 | — | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 22, 2023 | clinicaltrials |
| NCT00053209 | Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium | completed | Phase 2 | 46 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 22, 2023 | clinicaltrials |
| NCT01684098 | Safety and Efficacy of FalateScan (Technetium Tc 99m EC20) in Patients With Known Suspected Recurrent or Metastatic Cancer From a Solid Tumor | completed | Phase 2 | 40 | EndocyteINDUSTRY | 0 | Jun 22, 2023 | clinicaltrials |
| NCT04311580 | Intravesical Electromotive Mitomycin After Bacillus Calmette-Guérin Failure | completed | Phase 2 | 52 | University of Rome Tor VergataOTHER | 0 | Jun 22, 2023 | clinicaltrials |
| NCT00004223 | Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer | completed | Phase 2 | — | Eastern Cooperative Oncology GroupNETWORK | 3 | Jun 18, 2023 | clinicaltrials |
| NCT04440943 | A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies | completed | Phase 1 | 27 | Celldex TherapeuticsINDUSTRY | 1 | Jun 18, 2023 | clinicaltrials |
| NCT00002520 | Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer | completed | N/A | 434 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 15, 2023 | clinicaltrials |
| NCT00003701 | Combination Chemotherapy in Treating Patients With Bladder Cancer | completed | Phase 3 | 490 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 15, 2023 | clinicaltrials |
| NCT03852030 | Mind-Body Health in Uro-Oncology: Research Study | completed | N/A | 120 | Northwestern UniversityOTHER | 1 | Jun 13, 2023 | clinicaltrials |
| NCT05400291 | Gag-layer in the Urothelium of the Human Upper Urinary Tract | completed | — | 16 | Aarhus University HospitalOTHER | 1 | Jun 1, 2023 | clinicaltrials |
| NCT03065725 | Early Versus Late FDG-PET/CT in Bladder Cancer | completed | — | 179 | Jørgen Bjerggaard JensenOTHER | 1 | May 31, 2023 | clinicaltrials |
| NCT03385798 | Endo-GIA Versus Endowrist Stapler in Intracorporeal Urinary Diversion in Robotic Assisted Radical Cystectomy(EGIAES) | completed | N/A | 90 | Jørgen Bjerggaard JensenOTHER | 1 | May 31, 2023 | clinicaltrials |
| NCT04314245 | Diagnostic Evaluation of Urine DNA Methylation/Somatic Mutation Profiling for the Detection of Urothelial Carcinoma | completed | — | 1,170 | AnchorDx Medical Co., Ltd.INDUSTRY | 1 | May 24, 2023 | clinicaltrials |
| NCT03359239 | Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial Cancer | completed | Phase 1 | 10 | Matthew GalskyOTHER | 1 | May 16, 2023 | clinicaltrials |
| NCT03801954 | Implementation of Nutrition Education Videos for Patients Undergoing Radical Cystectomy | completed | — | 15 | University of Kansas Medical CenterOTHER | 1 | May 15, 2023 | clinicaltrials |
| NCT02043665 | CVA21 and Pembrolizumab in NSCLC & Bladder Cancer (VLA-009 STORM/ KEYNOTE-200)(STORM) | completed | Phase 1 | 85 | ViralyticsINDUSTRY | 3 | May 6, 2023 | clinicaltrials |
| NCT03841110 | FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | completed | Phase 1 | 37 | Fate TherapeuticsINDUSTRY | 1 | May 1, 2023 | clinicaltrials |
| NCT03758781 | IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors | completed | Phase 1 | 12 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 14, 2023 | clinicaltrials |
| NCT02371447 | VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer | completed | Phase 1 / Phase 2 | 39 | Swiss Cancer InstituteOTHER | 2 | Apr 13, 2023 | clinicaltrials |
| NCT03472274 | Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO)(DUTRENEO) | completed | Phase 2 | 101 | Fundacion CRIS de Investigación para Vencer el CáncerOTHER | 1 | Apr 13, 2023 | clinicaltrials |
| NCT04487457 | Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy(CINECI) | completed | — | 31 | University Hospital, ToursOTHER | 1 | Apr 6, 2023 | clinicaltrials |
| NCT05799456 | Glycosaminoglycan Scores as Early Detection Biomarkers in Bladder Urothelial Carcinoma | completed | — | 106 | Jens NielsenOTHER | 1 | Apr 5, 2023 | clinicaltrials |
| NCT04209192 | Antimicrobial Prophylaxis in Patients Who Underwent a Transurethral Resection of Bladder (TURB) | completed | Phase 2 | 75 | Instituto Nacional de Ciencias Medicas y Nutricion Salvador ZubiranOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT05324033 | Sensitivity of Multiparametric MRI in Differentiation Between Muscle Invasive and Non-muscle Invasive Urinary Bladder Cancer | completed | — | 30 | Helwan UniversityOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT03849469 | A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors(DUET-4) | completed | Phase 1 | 78 | Xencor, Inc.INDUSTRY | 1 | Mar 30, 2023 | clinicaltrials |
| NCT03775850 | A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors | completed | Phase 1 | 69 | Evelo Biosciences, Inc.INDUSTRY | 2 | Mar 24, 2023 | clinicaltrials |
| NCT03718754 | En-bloc vs Conventional Resection of Primary Bladder Tumor(eBLOC) | completed | Phase 3 | 384 | David D'AndreaOTHER | 1 | Mar 16, 2023 | clinicaltrials |
| NCT02983045 | A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors(PIVOT-02) | completed | Phase 1 / Phase 2 | 557 | Nektar TherapeuticsINDUSTRY | 8 | Mar 13, 2023 | clinicaltrials |
| NCT03330886 | A Study of the Safety of Atezolizumab in Patients With Advanced or Metastatic Urothelial Carcinoma in Argentina | completed | — | 13 | Hoffmann-La RocheINDUSTRY | 1 | Mar 13, 2023 | clinicaltrials |
| NCT03854721 | A Phase 1 Study of Intravesical VAX014 for Instillation in Subjects With Non-Muscle Invasive Bladder Cancer | completed | Phase 1 | 6 | Vaxiion TherapeuticsINDUSTRY | 1 | Mar 3, 2023 | clinicaltrials |
| NCT03689192 | Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors | completed | Phase 1 | 13 | Herlev HospitalOTHER | 1 | Feb 28, 2023 | clinicaltrials |
| NCT02217891 | IFACT: Incidental Findings in Advanced Cancer Therapy(IFACT) | completed | — | 60 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 13, 2023 | clinicaltrials |
| NCT02281383 | Evaluate the Response to 2 Induction Courses (12 Intravesical Instillations) of Bacillus Calmette-Guérin (BCG) for High Risk Superficial Bladder Cancer | completed | Phase 2 | 80 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT03058757 | The Effectiveness and Safety of Neoadjuvant Intravesical Mitomycin-C Instillation | completed | Phase 2 | 71 | National Cancer Center, KoreaOTHER_GOV | 1 | Jan 31, 2023 | clinicaltrials |
| NCT03212651 | Study Evaluating Neoadjuvant Pembrolizumab Monotherapy in Patients With Muscle-Invasive Bladder Cancer to Explore in Vivo the Mechanisms of Action of Pembrolizumab(PANDORE) | completed | Phase 2 | 41 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Jan 20, 2023 | clinicaltrials |
| NCT03434132 | Open Versus Robot Assisted Radical Cystectomy With Totally Intracorporeal Urinary Diversion. | completed | N/A | 116 | Regina Elena Cancer InstituteOTHER | 1 | Jan 19, 2023 | clinicaltrials |
| NCT04430842 | Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S | completed | Phase 1 | 15 | Quadriga Biosciences, Inc.INDUSTRY | 1 | Jan 18, 2023 | clinicaltrials |
| NCT03617913 | Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer | completed | Phase 2 | 2 | Mayo ClinicOTHER | 1 | Jan 6, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Aug 4, 2023source: clinicaltrials